US FDA wants evidence Opto-Pharm's Tuas plant remediation effort has worked
The US FDA has criticised Opto-Pharm Pte for selling unlicensed "drugs" and not bringing its Singapore manufacturing plant up to code.
Archives for March 29, 2017
Emisphere set to benefit as Novo Nordisk pushes oral diabetes pipeline
Novo Nordisk’s focus on developing oral versions of semaglutide and four other diabetes drugs could net drug delivery firm Emisphere over $200m.
update - US FDA declines to comment on potential investigation
EMA says CRO monitoring activity not location based
The EMA has stressed its monitoring of CROs is location independent after raising concerns about third Indian contractor in two years.